Platensimycin

From Wikipedia, the free encyclopedia

Platensimycin is an experimental new drug being trialed in an effort to combat MRSA.[1] Manufactured by a strain of Streptomyces platensis, it represents a previously unknown class of antibiotics, which acts by blocking enzymes involved in the synthesis of fatty acids,[2] which bacteria need to construct cell membranes (β-ketoacyl-ACP synthase I/II (FabF/B)). Currently being researched by Merck.

Recently, a first total synthesis of racemic platensimycin has been published.[3]

Image:platensimycin.gif

[edit] References

  1. ^ Jun Wang et al, Platensimycin is a selective FabF inhibitor with potent antibiotic properties, Nature 441, 358-361 (18 May 2006) PMID 16710421
  2. ^ Dieter Häbich, Franz von Nussbaum, ChemMedChem 2006, 1, 951–954. Platensimycin, a new antibiotic and "superbug challenger" from nature. PMID 16952137
  3. ^ K. C. Nicolaou, A. Li, D. J. Edmonds, Angew. Chem. 2006, 118, 7244 – 7248; Angew. Chem. Int. Ed. 2006, 45, 7086 – 7090. PMID 17013803

[edit] External links

This medical article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../p/l/a/Platensimycin.html"
In other languages